Patents by Inventor Muhammed Majeed

Muhammed Majeed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230381117
    Abstract: The present invention discloses methods and compositions for therapeutic management of obesity and high fat diet induced hyperlipidemia in mammals, using a composition comprising not less than 20% w/w bisdemethoxycurcumin, wherein the composition further comprises of 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin.
    Type: Application
    Filed: December 16, 2021
    Publication date: November 30, 2023
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
  • Publication number: 20230286893
    Abstract: The present invention discloses a compound, Vanillylidenechloroacetone (VCA)—1-Chloro-4-(4?-hydroxy-3?-methoxy-phenyl)-but-3-en-2-one, and the process of preparing the same. The invention also discloses a process for synthesis of Calebin-A from Vanillylidenechloroacetone.
    Type: Application
    Filed: March 3, 2023
    Publication date: September 14, 2023
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Nagarajan Muthukaman, Paradesi Naidu Pentakota
  • Patent number: 11744807
    Abstract: The present invention discloses a method for therapeutic management of pulmonary fibrosis in mammals using a composition comprising iso-garcinol or octahydrocurcumin or a combination of iso-garcinol and octahydrocurcumin. The composition is very suitable for treating pulmonary fibrosis due to viral infections, specifically COVID 19 and for improving lung function during prognosis.
    Type: Grant
    Filed: January 17, 2021
    Date of Patent: September 5, 2023
    Assignee: SAMI-SABINSA GROUP LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey
  • Patent number: 11707438
    Abstract: The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: July 25, 2023
    Assignee: SAMI-SABINSA GROUP LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur, Rajendran Ramanujam
  • Publication number: 20230201134
    Abstract: The invention discloses a composition and method for therapeutically managing a demyelinated disorder through remyelination. The invention includes a composition comprising Withaferin A and Bisdemethoxycurcumin (BDMC), and a pharmaceutically or nutraceutically acceptable excipients, which can be effectively formulated as tablets and capsules. The invention also covers use of composition for effectively managing a demyelinated disorder through remyelination.
    Type: Application
    Filed: December 29, 2021
    Publication date: June 29, 2023
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey
  • Publication number: 20230077004
    Abstract: The present invention relates to a composition for recovering from and/or alleviating a hangover, containing Garcinia indica. The composition for recovering from and/or alleviating a hangover of the present invention has an excellent recovery and/or alleviation effect on a hangover, and thus the composition for recovering from and/or alleviating a hangover has high industrial usefulness.
    Type: Application
    Filed: February 3, 2021
    Publication date: March 9, 2023
    Applicants: TOYO SHINYAKU CO., LTD.
    Inventors: Tomoyasu KAMIYA, Masamori Iwase, Muhammed Majeed
  • Publication number: 20220388939
    Abstract: The invention discloses novel intermediates in the synthesis of Calebin A represented by formula 3. The invention also covers processes for the synthesis of Calebin-A and its analogs using compounds of formula 3.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 8, 2022
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Nagarajan Muthukaman, Pentakota Paradesi Naidu
  • Patent number: 11491119
    Abstract: The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: November 8, 2022
    Assignee: SAMI-SABINSA GROUP LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur, Rajendran Ramanujam
  • Publication number: 20220347120
    Abstract: The invention discloses compositions comprising bisdemethoxycurcumin and methods for managing polycystic ovary syndrome (PCOS) and its associated conditions which include hormonal imbalance, obesity, hypothyroidism, hyperandrogenism, oxidative stress, inflammation, gut dysbiosis, hypercholesterolemia, cardiovascular complications, hyperglycemia and insulin resistance. The invention also discloses the potential of a curcuminoid composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin for use in the therapeutic management of PCOS.
    Type: Application
    Filed: April 29, 2022
    Publication date: November 3, 2022
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey
  • Patent number: 11458117
    Abstract: Disclosed are the uses of compositions containing not less than 10% w/w of Oroxylin A, not less than 10% w/w of Baicalein and not less than 2% w/w of Chrysin in inhibiting the activity and expression of ? secretase. The invention also discloses the reduction of amyloid content in PS-70 cells using the abovementioned composition. Further, the invention mentions the use of the composition for the therapeutic management of ? secretase mediated disorders.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: October 4, 2022
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Publication number: 20220304947
    Abstract: The present invention discloses use of a composition comprising enriched in bisdemethoxycurcumin, specifically a composition comprising not less than 20% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% curcumin in preventing the activation of viral spike proteins by inhibiting the activity of proteolytic enzymes and in inhibiting the replication and growth of pathogenic viruses, specifically SARS-CoV-2 in mammalian cells. The invention also discloses the potential of the above composition in managing SARS-CoV-2 induced infections.
    Type: Application
    Filed: October 13, 2021
    Publication date: September 29, 2022
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
  • Patent number: 11419906
    Abstract: The present invention discloses the potential of probiotic bacteria Bacillus coagulans individually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprising Bacillus coagulans and multi-enzyme complex in mammals.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: August 23, 2022
    Assignee: SAMI-SABINSA GROUP LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Kirankumar Beede, Sivakumar Arumugam, Shaheen Majeed
  • Patent number: 11413318
    Abstract: The present invention discloses a method for therapeutic management of atrophic gastritis and colitis using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins. The invention further discloses a method for preventing neoplastic transformation of mucosal cells in gastro-intestinal tract and improving gut barrier function in mammals using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: August 16, 2022
    Assignee: SAMI-SABINSA GROUP LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey, Shaheen Majeed
  • Publication number: 20220193006
    Abstract: The disclosed invention relates to a method and compositions for use in inhibiting proliferation, migration of Fibroblast-like Synoviocytes (FLS) in a subject. The invention also discloses a composition and method for regulating imbalance in T-helper 17 (Th17), T-cell. The composition disclosed comprises 20-50% BDMC, 10-25% w/w DMC and 30-50% w/w curcumin, further comprising boswellic acids and polysaccharides in the range of 35-50% w/w and 35-45% w/w.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 23, 2022
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
  • Publication number: 20220193178
    Abstract: A composition enriched with bisdemethoxycurcumin standardized to contain 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin. More specifically the invention discloses the potential of a composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin in the management of nephrotoxicity in mammals. The composition further comprises a Nigella sativa extract standardised to contain not less than 2% w/w thymoquinone and about 0.01%-10% w/w thymohydroquinone.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 23, 2022
    Inventors: Muhammed MAJEED, Kalyanam NAGABHUSHANAM, Lakshmi MUNDKUR, A. Muhamad IBRAHIM
  • Publication number: 20220193005
    Abstract: The invention discloses compositions and methods comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w for use in inhibiting Receptor for Advanced Glycation End-Products (RAGE) expression in a subject with chronic-inflammatory condition. The composition further comprises ?-amyrin palmitate (BAP).
    Type: Application
    Filed: December 16, 2021
    Publication date: June 23, 2022
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Ladshmi Mundkur
  • Patent number: 11351102
    Abstract: The present invention discloses a method for protecting mammalian skin against the harmful effects of UV radiation and environmental pollutants, using one or plant actives selected from group comprising a composition comprising not less than 10% w/w oroxylin A, not less than 10% w/w baicalein and not less than 2% w/w chrysin; 95% w/w oxyresveratrol; 95% w/w tetrahydrocurcumin; 90% w/w pterostilbene and a composition comprising at least 10% w/w ?-glucogallin and at least 10% w/w total mucic acid gallates. The invention also discloses a method for cleansing and rejuvenating mammalian skin, exposed to environmental pollutants and UV radiation using the aforesaid plant actives.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: June 7, 2022
    Assignee: SAMI-SABINSA GROUP LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
  • Patent number: 11332702
    Abstract: A probiotic-alcoholic beverage composition comprising Bacillus coagulans is disclosed herein wherein the said spore or vegetative cell of Bacillus coagulans exhibited high recovery, tolerability, compatibility and viability of spores and vegetative cells after brewing. Methods for brewing an alcoholic beverage composition comprising Bacillus coagulans wherein said spore or bacterium is added during pre-fermentation, during fermentation and post fermentation stages are also disclosed.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: May 17, 2022
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali, Shaheen Majeed, Kirankumar Beede
  • Publication number: 20220145244
    Abstract: The present invention discloses a method of isolating secondary metabolites, specifically arjunolic acid, from the calli and/or the suspension cultures derived from the pluripotent cambium tissue of Terminalia arjuna. The invention also discloses a method of inducing callus, establishing and maintaining suspension cultures of callus derived from the cambium of Terminalia arjuna for the isolation of secondary metabolites.
    Type: Application
    Filed: February 14, 2020
    Publication date: May 12, 2022
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Natarajan Sankaran, Sivakumar Arumugam, Muthuraman Gnanamani, Kulithalai Viswanathan Krishnamurthy, Ugraiah Amilineni
  • Publication number: 20220118032
    Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria.
    Type: Application
    Filed: November 8, 2021
    Publication date: April 21, 2022
    Applicant: SAMI-SABINSA GROUP LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Kirankumar Beede, Sivakumar Arumugam